title: FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
abstract: The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression-free survival, and safety/toxicity of neoadjuvant FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and chemoradiation in patients with locally advanced pancreatic cancer (LAPC). Patients with LAPC treated with FOLFIRINOX were identified via the Massachusetts General Hospital Cancer Center pharmacy database. Demographic information, clinical characteristics, and safety/tolerability data were compiled. Formal radiographic review was performed to determine overall response rates (ORRs). Twenty-two patients with LAPC began treatment with FOLFIRINOX between July 2010 and February 2012. The ORR was 27.3%, and the median progression-free survival was 11.7 months. Five of 22 patients were able to undergo R0 resections following neoadjuvant FOLFIRINOX and chemoradiation. Three of the five patients have experienced distant recurrence within 5 months. Thirty-two percent of patients required at least one emergency department visit or hospitalization while being treated with FOLFIRINOX. FOLFIRINOX possesses substantial activity in patients with LAPC. The use of FOLFIRINOX was associated with conversion to resectability in >20% of patients. However, the recurrences following R0 resection in three of five patients and the toxicities observed with the use of this regimen raise important questions about how to best treat patients with LAPC.
authors: Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. jfaris@partners.org
authors: Jason E
authors: JE
authors: Faris
authors: Lawrence S
authors: LS
authors: Blaszkowsky
authors: Shaunagh
authors: S
authors: McDermott
authors: Alexander R
authors: AR
authors: Guimaraes
authors: Jackie
authors: J
authors: Szymonifka
authors: Mai Anh
authors: MA
authors: Huynh
authors: Cristina R
authors: CR
authors: Ferrone
authors: Jennifer A
authors: JA
authors: Wargo
authors: Jill N
authors: JN
authors: Allen
authors: Lauren E
authors: LE
authors: Dias
authors: Eunice L
authors: EL
authors: Kwak
authors: Keith D
authors: KD
authors: Lillemoe
authors: Sarah P
authors: SP
authors: Thayer
authors: Janet E
authors: JE
authors: Murphy
authors: Andrew X
authors: AX
authors: Zhu
authors: Dushyant V
authors: DV
authors: Sahani
authors: Jennifer Y
authors: JY
authors: Wo
authors: Jeffrey W
authors: JW
authors: Clark
authors: Carlos
authors: C
authors: Fernandez-del Castillo
authors: David P
authors: DP
authors: Ryan
authors: Theodore S
authors: TS
authors: Hong
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage*; D008297:Male; D008404:Massachusetts; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
keywords: Chemoradiation; FOLFIRINOX; Locally advanced pancreatic cancer; Neoadjuvant; R0 resection
references: J Clin Oncol. 2009 May 1;27(13):2269-77
references: 19307501
references: J Clin Oncol. 2011 Nov 1;29(31):4066-8
references: 21969514
references: Radiat Oncol. 2012 Mar 02;7:28
references: 22385572
references: Ann Surg Oncol. 2010 Jan;17(1):194-205
references: 19856029
references: Ann Surg. 2005 Feb;241(2):295-9
references: 15650640
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: BMC Cancer. 2012 May 29;12:199
references: 22642850
references: J Clin Oncol. 2009 Apr 10;27(11):1806-13
references: 19273710
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: N Engl J Med. 2011 May 12;364(19):1817-25
references: 21561347
references: J Clin Oncol. 2011 Nov 1;29(31):4105-12
references: 21969502
references: Cancer. 2007 Jul 1;110(1):47-55
references: 17538975
references: Lancet. 2011 Aug 13;378(9791):607-20
references: 21620466
references: J Clin Oncol. 2007 Jan 20;25(3):326-31
references: 17235048
references: Ann Oncol. 2008 Sep;19(9):1592-9
references: 18467316
references: Cancer. 2012 Jun 15;118(12):3026-35
references: 22020923